Eyestem Receives CDSCO Approval to Initiate Phase 2 Randomized, Controlled Human Trials of Eyecyte-RPE™
Eyestem Receives CDSCO Approval to Initiate Phase 2 Randomized, Controlled Human Trials of Eyecyte-RPE™ India, 28 January 2026: Eyestem Research Pvt Ltd, a pioneering biotechnology company developing advanced scalable cell therapy solutions for blindness caused by dry age-related macular degeneration, has received approval from the Central Drugs Standard Control Organisation (CDSCO) to initiate the clinical trial […]







